Scarica l'app Stockscreener
20.73
1.49%
0.305
Dopo l'orario di chiusura:
20.73
0.005
+0.02%
Precedente Chiudi:
$20.42
Aprire:
$20.67
Volume 24 ore:
192.50K
Relative Volume:
0.71
Capitalizzazione di mercato:
$996.01M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-6.6965
EPS:
-3.0949
Flusso di cassa netto:
-
1 W Prestazione:
+1.05%
1M Prestazione:
-22.15%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$20.05
$21.60
Intervallo di 1 settimana:
$19.71
$23.50
Portata 52W:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Nome
Odyssey Therapeutics Inc
Settore
Industria
Telefono
(212) 841-1000
Indirizzo
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
20.73 | 985.68M | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Borsa (ODTX) Ultime notizie
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX - MarketBeat
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway By Investing.com - Investing.com Canada
Odyssey Therapeutics at Stifel forum: pipeline bets and cash runway - Investing.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P Global BMI Index - marketscreener.com
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to Russell 2500 Value Benchmark - marketscreener.com
Odyssey Therapeutics, Inc.(NasdaqCM:ODTX) added to Russell Small Cap Completeness Index - marketscreener.com
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
A biotech presentation is set for Sept. 23. Odyssey Therapeutics will take part online. - Stock Titan
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply - Yahoo Finance
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.ca
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Eastern Progress
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - MarketBeat
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - MarketBeat
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Odyssey Therapeutics Inc Azioni (ODTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Odyssey Therapeutics Inc Azioni (ODTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):